Rare diseases
Investigational molecules
Locations
Recruiting trials first
2 clinical trials in this condition
QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia
FranceTreatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia
CzechiaIn short
Diagnosing acute promyelocytic leukaemia requires swift action and specialized testing to identify this aggressive form of blood cancer. Because the disease can progress rapidly and cause life-threatening bleeding, healthcare providers often begin treatment even before final test results confirm the diagnosis.
If you notice unusual bleeding that won't stop, such as nosebleeds that continue despite applying pressure, bleeding gums when you brush your teeth, or unexplained bruises appearing on your skin, it's important to contact a healthcare provider right away. These symptoms may signal acute promyelocytic leukaemia, a rare but serious blood cancer that demands immediate attention.
Certain warning signs should prompt you to seek medical evaluation without delay. If you experience extreme fatigue that doesn't improve with rest, frequent infections that your body struggles to fight off, or unintentional weight loss, these could indicate problems with your blood cells. Women who notice unusually heavy menstrual bleeding, or anyone who sees blood in their urine or stool, should not wait to get these symptoms checked.
The condition most commonly affects adults around age 40, though it can occur at any age, including in children between eight and ten years old. Acute promyelocytic leukaemia accounts for approximately 10 to 15 percent of all acute myeloid leukaemia cases, with roughly 600 to 800 people diagnosed each year in the United States.
Because this disease progresses quickly and can cause dangerous complications within days, rapid diagnosis is critical. Healthcare providers often begin treatment as soon as they suspect acute promyelocytic leukaemia, even before receiving complete test results. This approach helps prevent the most serious complication: severe, uncontrolled bleeding that can be fatal if not addressed promptly.
Diagnosing acute promyelocytic leukaemia involves several specialized tests that help doctors identify abnormal cells and distinguish this condition from other types of blood cancer. The diagnostic process typically begins with blood tests and extends to more detailed examinations of your bone marrow and genetic material.
The first test your doctor will order is called a complete blood count, or CBC. This simple blood test measures the number of different types of cells circulating in your bloodstream. In acute promyelocytic leukaemia, the CBC typically reveals abnormal levels of white blood cells, red blood cells, and platelets. Your doctor looks for a condition called pancytopenia, which means you have low counts of all three main types of blood cells.
The white blood cell count can vary dramatically in people with this disease. Some patients have very low counts, while others show elevated numbers. What matters most is not just the quantity but the quality of these cells, as many will be immature and unable to function properly. The platelet count is especially important because low platelets contribute to the dangerous bleeding problems associated with this condition.
After the complete blood count, your doctor will examine a peripheral blood smear. In this test, a drop of your blood is spread thinly across a glass slide and viewed under a microscope. This allows specialists called pathologists to see the actual appearance and structure of your blood cells.
When looking at blood from someone with acute promyelocytic leukaemia, pathologists often notice distinctive features. They may see immature white blood cells called promyelocytes that contain high levels of tiny particles called granules. They might also spot unusual rod-shaped structures called Auer rods inside these abnormal cells. These visual clues help doctors suspect acute promyelocytic leukaemia even before receiving results from more complex tests.
To confirm the diagnosis, your healthcare provider will need to examine your bone marrow directly. This requires a procedure called a bone marrow biopsy, where a thin, hollow needle is inserted into a bone, usually in your hip, to remove a small sample of bone marrow tissue and fluid.
The bone marrow sample allows doctors to see whether abnormal promyelocytes have accumulated in large numbers. In acute promyelocytic leukaemia, these immature cells crowd out the healthy cells that normally produce red blood cells, white blood cells, and platelets. This explains why patients develop symptoms related to low blood counts, such as fatigue, infections, and bleeding problems.
Flow cytometry is a sophisticated laboratory technique that examines the surface of cells to identify specific protein patterns. During this test, pathologists check for particular markers on the abnormal cells that help confirm a diagnosis of acute promyelocytic leukaemia and distinguish it from other types of leukaemia.
The cells in acute promyelocytic leukaemia display unique characteristics that differ from other forms of acute myeloid leukaemia. By identifying these specific patterns, flow cytometry provides important information that guides treatment decisions and helps doctors predict how well a patient might respond to therapy.
The most definitive test for acute promyelocytic leukaemia looks for a specific genetic abnormality that causes the disease. In about 95 percent of cases, there is a chromosomal translocation, written as t(15;17), which occurs when pieces of chromosome 15 and chromosome 17 break off and swap places.
This rearrangement causes two genes, called PML and RARA, to fuse together. The resulting abnormal gene produces a fusion protein called PML-RARα that prevents white blood cells from maturing normally. Instead, these cells remain stuck at the promyelocyte stage and multiply uncontrollably.
Polymerase chain reaction, or PCR testing, is used to detect the PML-RARA fusion gene. This highly sensitive molecular test can identify even small numbers of abnormal cells. It's particularly valuable because it can detect the genetic abnormality even when routine chromosome analysis doesn't show the typical translocation. In some cases, the translocation is hidden or complex, making PCR testing essential for accurate diagnosis.
While the PML-RARA fusion is present in the vast majority of cases, approximately 5 percent of patients have different genetic rearrangements. These rare variants involve the RARA gene fusing with other partner genes instead of PML. Identifying these unusual cases is important because some respond differently to standard treatments.
Because bleeding complications are so dangerous in acute promyelocytic leukaemia, doctors perform specialized clotting tests to assess how well your blood can form clots. These tests measure various factors involved in the clotting process and help doctors understand your risk for severe bleeding.
Many patients with this condition develop a serious complication called disseminated intravascular coagulation, where the body uses up clotting factors faster than it can replace them. This leads to both abnormal clotting and excessive bleeding at the same time. Monitoring clotting function helps doctors manage this dangerous situation and guides decisions about transfusions and other supportive treatments.
If you're considering participating in a clinical trial for acute promyelocytic leukaemia, you'll undergo several standard tests to determine whether you're eligible. Clinical trials have specific entry requirements to ensure patient safety and to create groups of participants who can be fairly compared.
Most clinical trials require confirmation of the PML-RARA fusion gene through molecular testing such as polymerase chain reaction. This ensures that all participants truly have acute promyelocytic leukaemia rather than another form of acute myeloid leukaemia. Some trials may also test for specific variants of the fusion gene or other molecular markers that might affect how you respond to treatment.
Clinical trials often divide patients into risk groups based on their white blood cell count at diagnosis. Patients with a white blood cell count less than or equal to 10,000 per cubic millimeter are considered low risk, while those with counts greater than 10,000 are classified as high risk. This classification helps researchers determine the most appropriate treatment intensity and compare outcomes between similar groups of patients.
Your risk category influences which clinical trials you might be eligible for, as some studies specifically enroll low-risk patients while others focus on high-risk individuals. Researchers use these categories because they've learned that patients in different risk groups may benefit from different treatment approaches.
Before enrolling in a clinical trial, you'll need tests to evaluate how well your major organs are functioning. Blood tests check your liver and kidney function, as these organs play critical roles in processing medications. If your liver or kidneys aren't working properly, you might not be able to safely receive certain treatments being studied in clinical trials.
Heart function testing is also important, especially for trials involving certain chemotherapy drugs or arsenic trioxide, which can affect the heart's electrical system. Your doctor may order an electrocardiogram to measure your heart's rhythm and ensure it's safe for you to receive these medications.
Clinical trials require detailed baseline measurements before treatment begins. These might include repeated complete blood counts, additional bone marrow samples, and specialized molecular tests that can be compared to later results to measure how well the treatment is working. You may also undergo imaging tests such as chest x-rays or ultrasounds to check for disease in specific organs.
The trial protocol will specify exactly which tests are needed and how often they must be repeated during treatment. These regular assessments help researchers collect consistent data across all participants and allow doctors to quickly identify any concerning changes in your condition.
The outlook for people diagnosed with acute promyelocytic leukaemia has improved dramatically over the past several decades. Before the 1980s, this disease was considered one of the most fatal types of leukaemia, with patients often surviving less than a week without treatment. Today, thanks to advances in diagnosis and treatment, the prognosis is much more hopeful.
Most patients who receive appropriate treatment achieve complete remission, meaning all signs of the disease disappear. Complete remission rates approach 100 percent in patients treated with modern therapy combining all-trans retinoic acid and other targeted medications. However, the first few weeks after diagnosis remain critical, as early deaths from bleeding complications can still occur if the disease is not recognized and treated promptly.
Several factors influence an individual's prognosis. Patients classified as low risk based on their white blood cell count tend to have better outcomes than those with high-risk disease. Age also plays a role, with younger patients generally faring better than older individuals. The speed of diagnosis and initiation of treatment is perhaps the most important factor, as prompt treatment dramatically reduces the risk of fatal bleeding complications.
Patients who maintain complete remission for at least three years after treatment have a very low chance of the disease returning. Late relapses are uncommon, and many people who complete successful treatment can expect to live normal lifespans without the cancer coming back.
Survival rates for acute promyelocytic leukaemia have improved remarkably since the introduction of targeted therapies. Current statistics show that approximately 85 to 90 percent of people diagnosed with this disease achieve complete remission with modern treatment approaches.
Long-term survival rates are equally encouraging. Studies report that event-free survival rates exceed 90 percent with current treatment regimens that combine all-trans retinoic acid with chemotherapy or arsenic trioxide. This means more than 9 out of 10 patients remain alive and free from disease recurrence years after completing treatment.
Ten-year survival rates are estimated at approximately 80 to 90 percent, meaning that most people who are successfully treated for acute promyelocytic leukaemia can expect to survive at least a decade. Two-year overall survival probability and disease-free survival rates also exceed 90 percent with modern treatment protocols.
Around 75 percent of patients who achieve complete remission survive cancer-free for five years or longer. These survival statistics represent a tremendous improvement compared to historical outcomes and have transformed acute promyelocytic leukaemia from a rapidly fatal disease to one of the most curable forms of adult leukaemia.
It's important to remember that survival statistics are based on large groups of patients and may not predict what will happen to any individual person. Your own prognosis depends on many factors specific to your situation, including your age, overall health, how quickly you receive treatment, and how your disease responds to therapy.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
